Summary of Webinar Biotecnología y Empresas (IBt-UNAM & IBt-UANL)

This is an AI generated summary. There may be inaccuracies.
Summarize another video · Purchase summarize.tech Premium

00:00:00 - 01:00:00

This video discusses the importance of biotechnology and its impact on businesses. It highlights the work of 44 companies that are leading the market in vaccines, and points out that this has led to the acceptance of new paradigms in the approval process. The speaker concludes by discussing how students should be attentive to the stock market when researching biotechnology, as many public companies are present in Mexico and the U.S.

00:00:00 This video discusses the challenges and opportunities of biotechnology in Mexico, with a focus on pharmaceuticals. First, the presenter introduces the speaker, Dr. Laura Palomares, who is a biotecnologist and has worked on developing vaccines based on viruses. She also has a PhD in Bioengineering from the University of Mexico (UNAM). Dr. Palomares is currently a Professor at the UNAM Institute of Biotechnology and a Scientific Advisor to several Mexican companies and foreign governments. She is also a national level 3 investigator in the area of biomedical engineering. Next, the presenter introduces Dr. Luis Galán Wang, who is a biochemist and has a PhD from the University of New Mexico. He is currently an Assistant Professor at the UNAM Institute of Biotechnology. Dr. Wang has been a part of the vaccine development committee for Sepi, and has also been involved in the evaluation of biotechnology products. Next, the presenter briefly introduces Dr. Laura Valderrama, who is a biochemist and has a PhD from the University of Mexico. Dr. Valderrama is currently a Professor at the UNAM Institute of Biotechnology and has been part of the committee that developed Mexico's first recombinant protein. She
00:05:00 The biotechnology industry has undergone major changes in the health of humanity, with recombinant human insulin being approved in the 1980s, the first recombinant hepatitis B vaccine being developed in the 1990s, and the first fully human genome being sequenced in 2001. These milestones in biotechnology have been followed by the development of technologies such as chips for medical therapies in 2003, which was a major advance. Other major biotechnology developments include the ability to sequence the human genome completely, first organisms cells in 2007, and the development of personalized medicine with genome editing and progenitor cell replacement therapies.
00:10:00 A video titled "Webinar Biotecnología y Empresas (IBt-UNAM & IBt-UANL)" is followed by a 1-paragraph summary of the data found in the video. The video discusses how Mexico's low number of scientists and researchers in the field of biotechnology is hindering the country's ability to develop new, innovative pharmaceuticals and medical devices. Mexico is only at 50 percent of the world average in terms of publishing scientific papers per scientist. The lack of scientists and researchers in biotechnology also has a negative impact on the country's economy, as innovation in this field requires a strong foundation of scientific knowledge and a skilled workforce.
00:15:00 In this webinar, biotechnology and businesses (IBt-UNAM & IBt-UANL), Dr. Esther Ponce de León, discusses the importance of biocomparables, which are molecules that have been developed and are being manufactured by a Mexican company but are not sold in Mexico. Out of the 64 biocomparables that are registered in Mexico, six are Mexican companies. One Mexican company is the only company in Mexico that manufactures a biochemcial product from the beginning. In total, this Mexican company has produced four biochemcial products. The molecules that have biocomparables registrations are mostly monoclonal antibodies, such as bbva, and sumaritropoyetine (Eritropoyetine). These biocomparables are owned by foreign companies, but Mexican companies are also starting to register these molecules. Furthermore, during the last year, Mexican companies have made significant advances in their own vaccines research, such as development of a rotavirus vaccine. However, this kind of research is not possible to be done by a single institution, and the industry has been a vital partner in the development of these vaccines. Finally, Dr. Ponce de León discusses the importance of biocompar
00:20:00 This webinar discusses how universities in Mexico are working together to develop new biotechnology products. The two universities participating in the webinar discuss their research efforts in this area and explain how they use laboratories with high quality standards. The main focus of the webinar is the development of vaccines, and the universities discuss how they have been able to achieve this goal by working with laboratories with high quality standards and a good research infrastructure. The universities also mention the need for good clinical research practices, facilities for research animals, and manufacturing processes for clinical trials. Finally, the webinar discusses the importance of regulatory support during the product development process.
00:25:00 In this webinar, the Universidad Nacional Autónoma de México (UNAM) and the Universidad Autónoma de Nuevo León (UANL) discuss their research in the fields of biotechnology and business. The UNAM-UANL collaboration in building a peripheral unit of the Instituto de Bioquímica (IBt-UNAM) in Pachuca, Hidalgo, is described. The first Mexican center for diagnostics and therapeutics for pandemic preparedness is also described.
00:30:00 In this video, professor Luis Galán discusses his experience as a scientist, including his work as a bacteriologist, parasitologist, and chemist. He also provides an overview of his doctorate in microbiology, which focused on the study of Bacillus thuringiensis. Galán discusses how academia and business can work together to benefit society, and goes on to discuss the current state of the biotechnology industry. He ends the video by discussing how to identify and connect with businesses in the field of biotechnology.
00:35:00 In this video, the author discusses the areas of application of biotechnology, including avoiding public or private books about biotechnology. She then divides her talk into four parts: the academy, businesses, academia and its connection to businesses, and concluding remarks on the connection between business and academia. The first part of the talk focuses on general concepts that have influenced her life as both an administrative officer and in positions of leadership at the institute of biotechnology, both at UNAM and UANL. These include Albert Einstein's quote that "knowledge is nothing without imagination," and the knowledge that we need in order to use that knowledge. The second part of the talk addresses the problems and opportunities that academia and businesses face. The business section focuses on the need to focus on solving real problems, not just developing ideas. The problems that are most important to address are: the need to grow the population, adapt to changing technology, and take care of the environment. The third part of the talk is on business opportunities and challenges. The author discusses how we need to start thinking about problems in a different way, and how we need to start taking care of the environment. Finally, she talks about the need to address the issue of migration, and how we
00:40:00 This video discusses the problems that biotechnology and businesses face, and how they are likely to be some of the same problems that have been present for decades, for example. He said that the biotechnology industry has been stealing ideas from technology for 30 years, and it will become a big deal in solving these types of problems. He also mentioned AIDS in his talk, and how we've only been able to treat it since the 1980s because of biotechnology. We've been discussing some general issues in academia, and then talk about a specific case of a doctor, Laura Bueno, who is talking about the European Union's problems. Bueno discusses problems with vaccines, and how there are now over 100,000 different microbial species. She also talks about how complex it is to talk about more than 100,000 microbial species when one considers one microbial species can generate millions of subspecies. This topic becomes even more complicated when you consider organisms with the potential to cause extreme events. For example, viruses are one of the most abundant biological entities on Earth, and there are people who argue that we should be very happy because we have a virus causing these types of events. Bueno goes on to say that we need to do more studies on the impact of virus mutations,
00:45:00 This webinar is about biotechnology and businesses. It covers the business plan and requirements, and whether it is possible or not in the recovery of what was invested. If it is possible to continue the thread, the most difficult part is finding the funding. Who is going to found this? The market has been identified, the business plan is good, and finally, we are very tired. Many times, we turn back to this way and see some dependencies of the government. They are involved in this because really, we cannot have skilled personnel or direct all the personnel in one area to do all the functions in different areas. Therefore, people with skilled personnel are very interesting, and there is no good team when we look at it. This leads to us not being able to develop everything when we have this kind of action. In this case, it is specific to the area of academic research. I will not leave it like this at the moment. This is something that we should be reviewing in relation to the businesses in Mexico and international businesses, as well as looking at what is happening in recent technologies and how we can use them. We also have to remember that technology changes over time and is left behind in laboratories and universities. We need more investment to be able to
00:50:00 In this webinar, experts from the UNAM and UANL universities discuss the importance of biotechnology and its impact on businesses. They discuss the work of 44 companies that are leading the market in vaccines, and point out that this has led to the acceptance of new paradigmas in the approval process. They go on to say that since 2007, the time it has taken to develop a new drug has decreased by 7 years, and that this is due to the current economic climate. However, the lack of sales during these times has not stopped companies from continuing to research and develop new drugs - as seen with Améxica S.A.'s vaccine for tuberculosis, which is set to be released in 2019. This shift in focus is good for the part of technology because it allows businesses to reach a wider market, but it is also necessary for government support in order to make this possible. This webinar sheds light on the importance of biotechnology and its impact on the economy.
00:55:00 The speaker provides a brief history of biotechnology, discussing how profits from beer sales account for the majority of biotechnology's economic output. He then discusses the importance of academic research in the field, highlighting the case of Japan, which has developed a number of successful products in this area. He concludes by discussing how students should be attentive to the stock market when researching biotechnology, as many public companies are present in Mexico and the U.S.

01:00:00 - 01:20:00

This video discusses how biotechnology affects businesses and economies. It talks about the importance of universities and businesses collaborating together to create new products, and how this has led to Mexico's economy growing in recent years. The video also urges more books be written about the science of biotechnology, and that Mexico work to attract more skilled workers from other countries.

01:00:00 The speaker discusses how the stock market looks for companies that are looking for funding and how this affects what companies are willing to do. He also shares his experience of meeting with business owners many years ago and how they expressed regret that they were not better monitored by the university. He goes on to say that strong connections between universities and businesses are necessary in order to create new products and processes. If this connection is not established, other areas of the business may take precedence.
01:05:00 The presenter discussed important indicators of biotechnology industry growth, including patents generated and their impact on the development of businesses. They also mentioned five Mexican universities that are particularly active in biotechnology research. Overall, the presenter suggested that biotechnology companies should invest in patents and research and development (R&D). They also mentioned that in order to make this investment worthwhile, countries need to have a high GDP per capita in R&D.
01:10:00 This video discusses the importance of universities and businesses collaborating together to create new, innovative products. It also talks about the growth of Mexico's economy in the past few years, and how the country is now among the wealthiest in the world. Mexico is home to some of the world's wealthiest people, including three people who make up the top 10 richest people in the world. However, America's three richest people are also from Mexico, Greece, and China, with combined wealth of $3 trillion. In 2000, Mexico's wealth was 1.4 trillion dollars, but by 2020, it is expected to be 1.9 trillion dollars. This growth is due, in part, to the country's strong economy and its ability to generate new technology and business opportunities. However, Mexico also faces many challenges, including environmental pollution, deforestation, and a lack of skilled workers. In conclusion, the video urges universities, businesses, and other institutions to work together to create new products and wealth. It also suggests that more books be written about the science of biotechnology, and that Mexico work to attract more skilled workers from other countries.
01:15:00 This video discusses the importance of biotechnology and its impact on businesses and economies. The two experts, Dr. Laura Palomares (UNAM) and Dr. Valderrama (UANL), share their insights on the factors that led to the government of Hidalgo supporting this type of initiative. Laura Palomares comments that it is important to consider the needs of the government when presenting a biotechnology project to them. The two discuss the importance of research and its impact on economic growth, as well as the importance of having reliable statistics to support such a project. They also mention the importance of having a national biotechnology industry, and suggest that more companies should be founded in Mexico. Finally, they give some advice on establishing and running a successful biotechnology company.
01:20:00 The video discusses how biotechnology and businesses relate, with emphasis on how businesses play a role in improving products. It discusses how public and private companies are involved in biotechnology in Mexico, and provides statistics on the number of Mexican companies listed on the stock exchange in biotechnology-related fields. The speaker wishes to congratulate the authors of a recent study on Mexican biotechnology, and encourages more students to enter the field.